Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 6:04 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1609–1632 of 5,233 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Infection Clear all

Conditions: SARS-CoV-2 Infection
Interventions: COVID Prevention Program (CPP); Behavioral
Lead sponsor: San Diego State University; Other
Eligibility: 18 Years and older
Enrollment: 256 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: San Diego, California

Conditions: Catheter Infections, Spinal Catheter (Epidural) (Subdural); Complications, Infection or Inflammation
Interventions: Chlorhexidine impregnated patch (Biopatch); Device
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years to 85 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Cytomegalovirus Infections
Interventions: Not listed
Lead sponsor: IRCCS Azienda Ospedaliero-Universitaria di Bologna; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Cytomegalovirus, Organ Transplant, Kidney Transplant; Complications, Liver Transplant Complications, Simultaneous Liver-Kidney Transplantation; Complications
Interventions: Cytomegalovirus Immune Globulin Intravenous (Human) monthly for three months; Drug
Lead sponsor: Camille N. Kotton, MD; Other
Eligibility: 18 Years to 75 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 2
States / cities: Boston, Massachusetts • Dallas, Texas

Conditions: Postoperative Urinary Tract Infection, Pelvic Organ Prolapse, Stress Urinary Incontinence
Interventions: gentamicin sulfate, Catheter clamping only; Drug · Other
Lead sponsor: Kaiser Permanente; Other
Eligibility: 18 Years and older · Female only
Enrollment: 370 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 2
States / cities: La Jolla, California • San Diego, California

Conditions: Cytomegalovirus Retinitis, HIV Infections
Interventions: Foscarnet sodium; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years to 65 Years
Enrollment: 156 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1992
U.S. locations: 11
States / cities: Los Angeles, California • San Francisco, California • Miami, Florida + 7 more

Conditions: Non-infectious Uveitis
Interventions: AIN457, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 86 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 10
States / cities: Beverly Hills, California • Atlanta, Georgia • Louisville, Kentucky + 7 more

Conditions: Cellulitis, Insect Bites, Insect Stings
Interventions: POCUS Educational Intervention; Behavioral
Lead sponsor: New York City Health and Hospitals Corporation; Other
Eligibility: 3 Months to 20 Years
Enrollment: 71 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Colitis, HIV Infections
Interventions: Glutamic acid hydrochloride, Ganciclovir; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1998
U.S. locations: 5
States / cities: Birmingham, Alabama • San Francisco, California • St Louis, Missouri + 2 more

Conditions: Staphylococcus Aureus Colonization, Surgical Site Infections, Healthcare Associated Infections
Interventions: Screening and decolonization for SA carriers with the 3 drug bundle, No screening for SA, no screening, Nasal povidone-iodine on surgery day plus 2 CHG pre-op showers without screening., Nasal alcohol gel on surgery day plus 2 CHG pre-op showers without screening; Other
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years and older
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Hepatitis C, Chronic
Interventions: Tegobuvir (GS-9190), GS-9451, Pegasys®, Copegus®, Tegobuvir placebo, GS-9451 placebo; Drug · Biological
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 245 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 85
States / cities: Dothan, Alabama • Montgomery, Alabama • Phoenix, Arizona + 62 more

Conditions: HIV Prevention
Interventions: Descovy; Drug
Lead sponsor: Vivent Health; Other
Eligibility: 18 Years and older · Male only
Enrollment: 75 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2025
U.S. locations: 3
States / cities: Denver, Colorado • St Louis, Missouri • Milwaukee, Wisconsin

Conditions: Cytomegalovirus Retinitis, HIV Infections
Interventions: Sevirumab, Foscarnet sodium, Ganciclovir; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older
Enrollment: 167 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1998
U.S. locations: 20
States / cities: Birmingham, Alabama • Los Angeles, California • San Jose, California + 13 more

Conditions: Non-infectious Uveitis
Interventions: Calm Health - smartphone application; Other
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Cystic Fibrosis
Interventions: AZLI, Placebo to match AZLI, Tobramycin inhalation solution; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 6 Years and older
Enrollment: 107 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 71
States / cities: Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 62 more

Conditions: HIV Infection
Interventions: Not listed
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: Not listed
Enrollment: 113 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2005
U.S. locations: 10
States / cities: Los Angeles, California • Washington D.C., District of Columbia • Fort Lauderdale, Florida + 7 more

Conditions: Renal Failure
Interventions: Group 1: Alternative Fistula, Group 2: Forearm AV Graft; Other
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: COVID-19
Interventions: Standard of care, Apremilast, Apremilast placebo, Lanadelumab, Lanadelumab placebo, Zilucoplan, Zilucoplan placebo; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years and older
Enrollment: 515 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 21
States / cities: Anniston, Alabama • Bakersfield, California • Chula Vista, California + 17 more

Conditions: Hepatitis C, Pregnancy
Interventions: ledipasvir/sofosbuvir; Drug
Lead sponsor: Catherine Chappell; Other
Eligibility: 18 Years to 39 Years · Female only
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: COVID-19
Interventions: Not listed
Lead sponsor: ClinOne, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 790 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Greenwood Village, Colorado

Conditions: Sepsis, Respiratory Distress Syndrome, Respiratory Distress Syndrome, Adult
Interventions: vasoactive intestinal peptide; Drug
Lead sponsor: Stony Brook University; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1998
U.S. locations: 2
States / cities: Northport, New York • Stony Brook, New York

Conditions: Cytomegalovirus Retinitis, HIV Infections
Interventions: Foscarnet sodium, Ganciclovir; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1993
U.S. locations: 6
States / cities: Los Angeles, California • San Francisco, California • St Louis, Missouri + 3 more

Conditions: Anti-biotic Resistance
Interventions: VSL#3, sugar pill (placebo); Dietary Supplement
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years and older
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Liver Fibrosis, Hepatic Fibrosis, Liver Cirrhosis, Hepatic Cirrhosis
Interventions: IDN-6556, Placebo; Drug
Lead sponsor: Conatus Pharmaceuticals Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 35
States / cities: Coronado, California • La Jolla, California • Loma Linda, California + 24 more

Search by objective public record fields.

Intervention to Prevent Household and Community Spread of COVID-19 Among Latinos

Post-Operative Colonization Rates of Femoral Nerve Catheters Treated With Chlorhexidine-Impregnated Patch

Ganciclovir Resistant/Refractory Cytomegalovirus Infection in SOT Recipients and HSCT Patients

Strategic Help With Immunoglobulin to Enhance Protect Against Late Disease (CMV)

Gentamicin Intravesical Efficacy for Infection of Urinary Tract

A Phase II Dose-Ranging, Open-Labelled Trial of Foscarnet Salvage Therapy for AIDS Patients With Sight-Threatening CMV Retinitis Who Cannot Be Treated With Ganciclovir Due To Myelosuppression or Treatment Failure

Safety and Efficacy of AIN457 in Patients With Quiescent Non-infectious Uveitis

Point-of-Care Ultrasound Educational Initiative for Insect Bites

A Randomized Comparative Pharmacokinetic Study of Oral Ganciclovir After Treatment With Intravenous Ganciclovir for Cytomegalovirus Gastrointestinal Disease in AIDS Patients

Effectiveness of Screening and Decolonization of S. Aureus to Prevent S. Aureus Surgical Site Infections in Surgery Outpatients

A Study of Response-Guided Duration of Combination Therapy With GS-9451, Pegasys® and Copegus® With and Without Tegobuvir (GS-9190) in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C

Telehealth as a Modality to Increase the Uptake of PrEP Services in Black and Latino: "e-PrEP"

Comparison of Two Methods in the Treatment of Cytomegalovirus of the Eyes in Patients With AIDS

Mindfulness Approach for Reducing Anxiety and Gloom in Ocular Inflammatory Diseases

Phase 3 Study of Aztreonam for Inhalation Solution (AZLI) in a Continuous Alternating Therapy Regimen for the Treatment of Chronic Pseudomonas Aeruginosa Infection in Patients With CF

Evaluation of Genetic Markers as Explanations for the Observed Differences in Disease Progression in HIV+ Youth

Randomized Fistula Study

Study of Multiple Candidate Agents for the Treatment of COVID-19 in Hospitalized Patients

Study of Hepatitis C Treatment During Pregnancy

Wearable Diagnostic for Detection of COVID-19 Infection

Phase I Study of Vasoactive Intestinal Peptide in Patients With Acute Respiratory Distress Syndrome and Sepsis

A Study of Foscarnet Plus Ganciclovir in the Treatment of Cytomegalovirus of the Eye in Patients With AIDS Who Have Already Been Treated With Ganciclovir

A Pilot Trial to Determine the Efficacy of VSL#3 for Reducing Colonization by VRE

A Trial of IDN-6556 in Post Orthotopic Liver Transplant for Chronic HCV